about
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cellsPhase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverOncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapyProgress and problems with the use of suicide genes for targeted cancer therapyNeuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virusMathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics.Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityCancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expressionOncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Current status of gene therapy for brain tumors.Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47deltaCharacterization of a replication-incompetent pseudorabies virus mutant lacking the sole immediate early gene IE180.HSV-1 Cgal+ infection promotes quaking RNA binding protein production and induces nuclear-cytoplasmic shuttling of quaking I-5 isoform in human hepatoma cells.Oncolytic bluetongue viruses: promise, progress, and perspectivesCytolytic replication of echoviruses in colon cancer cell linesDesign and application of oncolytic HSV vectors for glioblastoma therapy.Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.A scalable approach to prevent teratoma formation of human embryonic stem cellsUV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsIdentification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics.Perspectives in vector development for systemic cancer gene therapy.Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapyA combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.Possible DNA viral factors of human breast cancerMeasles virus for cancer therapy.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Chronic activation of the D156A point mutant of Channelrhodopsin-2 signals apoptotic cell death: the good and the badAdvances with the use of bio-inspired vectors towards creation of artificial viruses.HSV Recombinant Vectors for Gene Therapy.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Contribution of MS-Based Proteomics to the Understanding of Herpes Simplex Virus Type 1 Interaction with Host Cells.Bacterial vectors for imaging and cancer gene therapy: a review.Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
P2860
Q24618562-BC9303C7-95EA-484B-89ED-B5A22B239B8BQ24633957-7531C737-2F7B-41E9-8370-F6188EA327C3Q26998111-2FE11703-9664-4D44-9621-072BCA425CDAQ28262370-1FA4EECE-7352-4417-9F98-F60239FBC507Q28474594-417B6272-9DF4-465F-829F-DB4C0733209FQ33259239-A37BF330-647B-49CC-A2B2-AE147B695122Q33743847-4C2B48B7-7586-466C-AB05-35433993088AQ33903856-9E6C1A93-C528-4E2B-A262-C5B52DE56CF8Q33995471-83E8C5DC-0527-4432-9466-23E9A3BACD2FQ34318157-DE38A8E0-0095-485B-A450-078B8CC0B5ADQ34423157-5AA3B4F1-5F66-4D84-8BF0-421CA38D3638Q34530481-B9254EF2-86F8-42FF-B98B-603952521B71Q35026933-8E150683-8F3A-4C41-90D3-CAA4DBF143A5Q35084491-702382B7-B236-4C45-8786-E0A57889C523Q35541517-CAC691F5-26A0-481C-AFF4-595217670236Q35559877-7EF3C8D2-98D3-4252-9B9D-96A109301953Q35876172-3EA1DE08-7D41-4F67-BCCD-BEBDF887880BQ36294776-91F14046-4A7D-4FC4-8435-8DBF32618B37Q36966726-5222153B-1F09-42E0-BA8C-C874C32A4AB7Q37031918-0380B164-340D-4E61-8FFB-F5D7AD19A85CQ37103315-F563353F-E589-4664-8446-717271EB6F24Q37138701-0CBF81B6-27A5-4EDA-B133-E80CAE083CF1Q37154463-CE0C27D6-2938-428E-85C0-B8A34A8C12D0Q37214820-6F3F66D3-1424-444F-91AD-743A2BC76A7EQ37267785-C1BB6E3A-A9E5-498C-A13E-D18A5CDEDDA8Q37317390-F26911CE-3667-45A2-9575-A0BF6619BE92Q37328294-0BB1124F-E9A1-451C-8D1F-AAF81E349306Q37388577-121D126D-1220-4A8C-ABEC-838A9711F14DQ37564490-5628D154-4AE3-439E-94C6-3545C94B6121Q37603311-32B7143F-24AB-477E-A70C-6B305D52CDFEQ37691446-C8DD3F8E-11B0-4C6A-9075-F2B66E099FC8Q37787777-0545D1F7-0523-416F-AC86-776D45A1B7B6Q37834445-4B2525BF-2158-4085-9B60-A4F747CCAB0FQ37899223-17CD25B8-3902-46D1-BA71-F1A5074F2459Q37997767-00030511-2408-4DC0-9F62-D6D53F1230E6Q38045229-1E04D40D-7FF2-4BEB-8EE4-994F1777211BQ38513435-55C09532-139B-4EDD-AC86-759E3CB89B3AQ38630561-BDBEFD84-6111-4C11-9396-9F16874C6109Q38753120-DFC9DC6F-8E04-41E8-A8A3-9E65525D3502Q38781322-AD05A5E4-6CD9-43FE-9B9B-9ACEACE5F20B
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Herpes simplex virus 1 (HSV-1) for cancer treatment.
@ast
Herpes simplex virus 1 (HSV-1) for cancer treatment.
@en
type
label
Herpes simplex virus 1 (HSV-1) for cancer treatment.
@ast
Herpes simplex virus 1 (HSV-1) for cancer treatment.
@en
prefLabel
Herpes simplex virus 1 (HSV-1) for cancer treatment.
@ast
Herpes simplex virus 1 (HSV-1) for cancer treatment.
@en
P2860
P356
P1433
P1476
Herpes simplex virus 1 (HSV-1) for cancer treatment.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700946
P577
2006-04-07T00:00:00Z
P5875
P6179
1038844573